Pemazyre (Pemigatinib): A Targeted Therapy for Bile Duct Cancer and MLN

Understanding Pemazyre (Pemigatinib) for Bile Duct Cancer and Myeloid Lymphoid Neoplasms

Pemazyre, with the active ingredient pemigatinib, is a targeted therapy medication prescribed for adults with specific types of bile duct cancer and myeloid lymphoid neoplasms (MLN). It is available as an oral tablet in three strengths: 4.5 mg, 9 mg, and 13.5 mg. This drug works by targeting certain genetic mutations, offering a new avenue for treatment when other therapies have not been successful or the cancer has recurred.

What is Pemazyre Used For?

Pemazyre is approved for adults with bile duct cancer (cholangiocarcinoma) that has a specific genetic mutation involving the fibroblast growth factor receptor (FGFR) protein. This cancer should either have spread to other parts of the body or nearby tissues and cannot be surgically removed, or it should have been previously treated with other cancer medications. For adults with MLN, Pemazyre is prescribed if the cancer also has an FGFR genetic mutation and has not responded to or has returned after previous treatments.

How Pemazyre Works (Mechanism of Action)

Pemazyre is a type of targeted therapy. It specifically inhibits the FGFR protein, which plays a role in the growth and spread of certain cancers. By blocking this protein, Pemazyre helps to slow down or stop the growth of cancer cells that rely on FGFR signaling. The effectiveness of Pemazyre is linked to the presence of specific FGFR genetic mutations in the cancer cells.

Dosage and Administration

The dosage of Pemazyre is determined by your doctor based on your specific condition and response to treatment. For the treatment of MLN, a common starting dose is 13.5 mg taken orally once per day. For bile duct cancer, the dosage might be adjusted based on side effects experienced. It is crucial to take Pemazyre exactly as prescribed by your doctor and not to alter the dosage without medical advice. If you suspect you have taken too much Pemazyre, contact your doctor or a poison control center immediately. In case of severe symptoms, seek emergency medical attention.

Potential Side Effects

Like all medications, Pemazyre can cause side effects, ranging from mild to serious. It is important to be aware of these potential effects and to report any concerns to your healthcare provider.

Common Mild Side Effects:

• Nail Toxicity: This can include nail separation, ingrown nails, and thickening of the nails.
• Digestive Issues: Such as abdominal pain, nausea, vomiting, constipation, and diarrhea.
• Pain: General discomfort or pain.

Serious Side Effects:

Serious side effects can occur and require immediate medical attention. These may include:

• Allergic Reactions: Symptoms can include rash, itching, swelling, dizziness, or trouble breathing. If you experience an allergic reaction, call your doctor immediately or seek emergency services if you believe you are having a medical emergency.
• Other Serious Effects: Your doctor will monitor you for other potential serious side effects, which can vary.

It is essential to discuss all potential side effects with your doctor or pharmacist. They can provide guidance on managing side effects and when to seek medical help.

Drug Interactions

Pemazyre interacts with certain enzymes in the body, particularly Cytochrome P450 3A4 (CYP3A4), which is involved in breaking down drugs. Medications that affect CYP3A4 activity can alter the levels of Pemazyre in your body, potentially increasing the risk of side effects or reducing its effectiveness. Always inform your doctor about all medications, supplements, and herbal products you are taking to avoid harmful interactions.

Pregnancy and Breastfeeding Considerations

Pemazyre is not recommended for use during pregnancy or breastfeeding. It is recommended that females who can become pregnant use effective contraception during treatment with Pemazyre and for at least one week after the last dose. Males with partners who can become pregnant should also use contraception during treatment and for at least one week after the last dose. It is not known if Pemazyre passes into breast milk or what effects it may have on a breastfed infant. Therefore, breastfeeding is not recommended while taking Pemazyre and for at least one week after stopping treatment.

Treatment Duration and Response

The time it takes to see a reduction in tumor size can vary. In some clinical studies, tumor shrinkage was observed within one month of starting treatment, while in others, it took up to seven months. Your doctor will monitor your response to treatment and adjust the plan as needed.

Important Precautions

Pemazyre is a prescription medication and should only be used under the guidance of a qualified healthcare professional. It is crucial to attend all scheduled appointments and follow your doctor's instructions carefully. If you experience any severe side effects or have concerns about your treatment, do not hesitate to contact your healthcare provider.

When to Consult a Doctor

You should consult your doctor immediately if you experience any of the following:

• Signs of a serious side effect, such as severe allergic reaction or other concerning symptoms.
• If you think you have taken too much Pemazyre.
• If you have questions or concerns about your treatment.

In case of a medical emergency, always call 911 or your local emergency number.

Note on Accelerated Approval

For bile duct cancer, Pemazyre received accelerated approval from the FDA based on early clinical studies. Full approval is pending further studies. This means the drug is available for use while more extensive research is conducted to confirm its benefits and safety.